| P50 | author | Ettore Beghi | Q47264144 |
| | Giorgia Giussani | Q47710160 |
| P2860 | cites work | Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study | Q30540714 |
| | Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug | Q38665970 |
| | Treatment Outcomes in Patients with Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study | Q47245856 |
| | Mortality in Dravet syndrome | Q47888090 |
| | Cannabinoids for epilepsy: What do we know and where do we go? | Q48162585 |
| | Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial | Q50109024 |
| | Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. | Q52655447 |
| | Heart rate variability in epilepsy: A potential biomarker of sudden unexpected death in epilepsy risk | Q58831398 |
| | Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry | Q61849442 |
| | Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome | Q62868130 |
| P433 | issue | 1 | |
| P304 | page(s) | 7-8 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Lancet Neurology | Q15755067 |
| P1476 | title | Treatment of epilepsy in light of the most recent advances | |
| P478 | volume | 18 | |